Table 3. Differences in Stage Distribution of Expression-Stratified Populations.
# | Direction with survival | Gene name | Lower expression | Higher expression | p-value for differences between Stages 1 + 2 vs. 3 + 4 (χ2) | ||
---|---|---|---|---|---|---|---|
Stages 1 + 2 |
Stages 3 + 4 |
Stages 1 + 2 |
Stages 3 + 4 |
||||
1 | + | HLA-DRA | 85 | 87 | 115 | 57 | 0.066 |
2 | − | GPR84 | 129 | 43 | 78 | 94 | p < 0.0001 |
3 | − | FCGR1B | 130 | 42 | 72 | 100 | p < 0.0001 |
4 | − | FCGR1C | 128 | 44 | 69 | 103 | p < 0.0001 |
5 | − | AIF1 | 119 | 53 | 88 | 84 | 0.044 |
6 | − | IL10RA | 113 | 59 | 87 | 85 | 0.2772 |
7 | − | SP140 | 118 | 54 | 75 | 97 | p < 0.0001 |
8 | − | LAIR1 | 122 | 50 | 81 | 91 | p < 0.0001 |
9 | − | FCGR1A | 132 | 40 | 72 | 100 | p < 0.0001 |
10 | − | SLAMF8 | 122 | 50 | 88 | 84 | 0.0132 |
11 | − | BATF | 126 | 46 | 69 | 103 | p < 0.0001 |
12 | − | HAMP | 133 | 39 | 77 | 95 | p < 0.0001 |
13 | − | CD72 | 124 | 48 | 75 | 97 | p < 0.0001 |
14 | − | PARVG | 113 | 59 | 82 | 90 | 0.0484 |
15 | − | TRPM2 | 114 | 58 | 91 | 81 | 0.6864 |
16 | − | HCST | 124 | 48 | 81 | 91 | p < 0.0001 |
17 | + | XCR1 | 86 | 86 | 116 | 56 | 0.066 |
18 | − | FCGR3A | 116 | 56 | 93 | 79 | 0.6644 |
19 | − | LILRB1 | 121 | 51 | 86 | 86 | 0.0088 |
20 | − | ZNF80 | 111 | 61 | 80 | 92 | 0.0484 |
21 | − | RAC2 | 113 | 59 | 74 | 98 | p < 0.0001 |
22 | − | WAS | 117 | 55 | 77 | 95 | p < 0.0001 |
23 | − | CYTH4 | 114 | 58 | 84 | 88 | 0.0704 |
24 | − | SPI1 | 120 | 52 | 83 | 89 | 0.0044 |
25 | − | TNFSF13B | 126 | 46 | 72 | 100 | p < 0.0001 |
26 | − | MYO1F | 115 | 57 | 88 | 84 | 0.1936 |
27 | − | GNA15 | 109 | 63 | 89 | 83 | 1 |
28 | + | LILRA4 | 92 | 80 | 115 | 57 | 0.6776 |
29 | − | CTLA4 | 115 | 57 | 81 | 91 | 0.0132 |
30 | − | CCL5 | 122 | 50 | 76 | 96 | p < 0.0001 |
31 | − | IFNG | 121 | 51 | 76 | 96 | p < 0.0001 |
32 | − | CXCL13 | 128 | 44 | 72 | 100 | p < 0.0001 |
33 | − | FERMT3 | 112 | 60 | 86 | 86 | 0.2816 |
34 | − | C1QA | 114 | 58 | 84 | 88 | 0.0704 |
35 | − | IL2RG | 125 | 47 | 77 | 95 | p < 0.0001 |
36 | − | CD80 | 108 | 64 | 89 | 83 | 1 |
37 | − | C1QB | 116 | 56 | 87 | 85 | 0.0924 |
38 | − | PTPN7 | 125 | 47 | 73 | 99 | p < 0.0001 |
39 | − | FCER1G | 126 | 46 | 80 | 92 | p < 0.0001 |
40 | − | ARHGAP9 | 120 | 52 | 85 | 87 | 0.0088 |
41 | − | LILRB2 | 106 | 66 | 89 | 83 | 1 |
42 | − | DERL3 | 119 | 53 | 79 | 93 | p < 0.0001 |
43 | − | LILRB3 | 117 | 55 | 80 | 92 | 0.0044 |
44 | − | JSRP1 | 122 | 50 | 78 | 94 | p < 0.0001 |
The counts represent the distribution of patients who were diagnosed with the mentioned pathological stages. Values in the column “direction with survival”: “−” = more survivors in the low-expression third. “+” = more survivors in the higher-expression third. Significance values in the right column are shown after multiple testing correction and the p-values in bold were significant after correction.